27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- CANbridge Pharmaceuticals Inc has entered into a strategic collaboration and licensing agreement with LogicBio Therapeutics Inc (NASDAQ: LOGC) to develop, manufacture and commercialize gene therapy candidates for treatments for Fabry and Pompe diseases.
- The candidates will be based on LogicBio's adeno-associated virus (AAV) sL65, the first capsid produced from the LogicBio sAAVy platform.
- The agreement also includes options for the development of AAV sL65-based treatments for two additional indications.
- CANbridge is also granted an option to an exclusive license for LB-001, an investigational in-vivo gene-editing technology based on the GeneRide platform to treat methylmalonic acidemia (MMA) in Greater China (China, Taiwan, Hong Kong, and Macau).
- Under the terms of the agreement, LogicBio will receive an upfront payment of $10 million for Fabry and Pompe disease candidates.
- Upon exercising the option for LB-001, CANbridge would assume responsibility and costs for all future development.
- The agreement also milestone payments for up to $581 million and up to double-digit royalties on net sales.
- Additionally, LogicBio signed a research collaboration and exclusive option agreement with Daiichi Sankyo (OTC:DSKYF).
- The companies will collaborate on developing treatments for two undisclosed indications based on GeneRide, LogicBio's proprietary gene insertion platform.
- The financial terms of the collaboration are not disclosed.
- Price Action: LOGC shares are up 0.17% at $6.011 during the market session on the last check Tuesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!